Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525

Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
  English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |   
lüll Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies Yau T; Chan P; Ching Chan Y; Wong BC; Liang R; Epstein RJAliment Pharmacol Ther 2008[Jun]; 27 (11): 997-1005BACKGROUND: The field of colorectal cancer chemotherapy has been transformed by the advent of molecule-specific drugs. Combined use of such drugs enhances tumour response rates, but controlled data quantifying the relative efficacy and cost-effectiveness of different drug combinations on overall survival remain scarce. AIM: To conduct an overview of published clinical trials in advanced colorectal cancer, with the objective of framing provisional approaches to current management. METHODS: An NCBI/PubMed search was performed using the strings, 'colorectal cancer' ('metastatic' or 'advanced' or 'palliative') and ('chemotherapy' or 'drug therapy' or 'targeted' or 'target-specific' or 'molecularly-targeted'). RESULTS: Combinations of target-specific drugs (with or without the DNA-alkylating agent oxaliplatin) have substantially enhanced colorectal cancer time to progression over the last decade and have also expedited surgical resection of liver metastases. Disease-free survival, overall survival and quality of life are favourably influenced. CONCLUSIONS: Target-specific drugs improve palliative efficacy in the setting of advanced colorectal cancer. However, key issues persist as to the cost-effectiveness of these newer drug treatments, and further controlled trials are needed to resolve this important debate.|Antineoplastic Agents/economics/*therapeutic use[MESH]|Antineoplastic Combined Chemotherapy Protocols/economics/*therapeutic use[MESH]|Chemotherapy, Adjuvant[MESH]|Clinical Trials as Topic[MESH]|Colorectal Neoplasms/*drug therapy[MESH]|Cost-Benefit Analysis[MESH]|Drug Delivery Systems[MESH]|Humans[MESH] |